Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T21:38:25.769Z.
Calculation as of: 2026-10-06T21:38:25.769Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8b72fc44080d8c671fb5883057af471201fb64a542d8aebba0fac2689ec384f4
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2011-08-09.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
PRICE/OCF RATIO AVG TTM
N/A
PRICE/OCF RATIO AVG 3Y
N/A
PRICE/OCF RATIO AVG 5Y
N/A
PRICE/OCF RATIO AVG 10Y
N/A
PRICE/OCF RATIO AVG 15Y
N/A
PRICE/OCF RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Sunshine Biopharma, Inc.
Market Cap
$946332.00
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.01M
Price/OCF Ratio
N/A
TTM Avg
60791.74
3Y Avg
60791.74
5Y Avg
60791.74
Market Cap
$868077.00
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$838843.00
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$824550.00
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sunshine Biopharma, Inc. (SBFM) | $946332.00 | N/A | N/A | N/A | N/A |
| GlucoTrack, Inc. (GCTK)vs › | $901902.00 | N/A | N/A | N/A | N/A |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.01M | N/A | 60791.74 | 60791.74 | 60791.74 |
| Bone Biologics Corporation (BBLG)vs › | $868077.00 | N/A | N/A | N/A | N/A |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $838843.00 | N/A | N/A | N/A | N/A |
| Ridgetech, Inc. (RDGT)vs › | $835994.00 | N/A | 0.30 | 0.38 | 0.32 |
| Decoy Therapeutics Inc. (DCOY)vs › | $824550.00 | N/A | N/A | N/A | N/A |
| Clearmind Medicine Inc. (CMND)vs › | $1.08M | N/A | N/A | N/A | N/A |
| Propanc Biopharma, Inc. (PPCB)vs › | $1.12M | N/A | N/A | N/A | N/A |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.13M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PRICE/OCF RATIO |
|---|---|
| 2011-08-09 | 11083.05 |
| 2011-08-08 | 13640.68 |
| 2011-08-05 | 16198.31 |
| 2011-08-04 | 16198.31 |
| 2011-08-03 | 19437.97 |
| 2011-08-02 | 21313.57 |
| 2011-08-01 | 23871.19 |
| 2011-07-29 | 22166.11 |
| 2011-07-28 | 20631.53 |
| 2011-07-27 | 17562.38 |
| 2011-07-26 | 16198.31 |
| 2011-07-25 | 16368.82 |
| 2011-07-22 | 16198.31 |
| 2011-07-21 | 16198.31 |
| 2011-07-20 | 13657.73 |
| 2011-07-19 | 16709.84 |
| 2011-07-18 | 17221.36 |
| 2011-07-15 | 17221.36 |
| 2011-07-14 | 16027.80 |
| 2011-07-13 | 17391.87 |
| 2011-07-12 | 16198.31 |
| 2011-07-11 | 11935.60 |
| 2011-07-08 | 7672.88 |
| 2011-07-07 | 6820.34 |
| 2011-07-05 | 7161.36 |
| 2011-06-30 | 9377.97 |
| 2011-06-29 | 8525.43 |
| 2011-06-28 | 8525.43 |
| 2011-06-27 | 5626.78 |
| 2011-06-23 | 5967.80 |
| 2011-06-22 | 6820.34 |
| 2011-06-17 | 7672.88 |
| 2011-06-08 | 6308.82 |
| 2011-05-25 | 7672.88 |
| 2011-05-19 | 7672.88 |
| 2011-05-13 | 7331.87 |
